A world-class pharmaceutical research and development company, and the parent company of Filament Health, advancing natural psychedelic medicines for psychiatric and neurological conditions, helping people rediscover health.
Our Mission
Rhelion Life Sciences is a world-class pharmaceutical research and development company dedicated to the discovery and development of natural psychedelic medicines for psychiatric and neurological conditions. We believe that rigorous science, patient-centred design, and disciplined development can change what is possible in mental and brain health.
As the parent company of Filament Health, Rhelion brings together a fully integrated natural psychedelic drug discovery and development platform:
What We Do
Research programs addressing mood, anxiety, and treatment-resistant psychiatric disorders.
Therapeutic candidates targeting neurodegenerative and neuro-inflammatory disease.
Our Pipeline
Botanical Psilocybin
Our standardized natural psilocybin drug candidate, studied across 80+ clinical trials worldwide, including FDA-authorized programs in depression, PTSD, cancer-related distress, and substance use disorders. Its proprietary extraction, purification, and stabilization technology delivers 36-month stability and a full spectrum of doses from microdosing to 25 mg, protected by a portfolio of 76 issued patents across 13 patent families in multiple jurisdictions.
Botanical Ibogaine
Our botanical ibogaine drug candidate in development for substance use disorders, derived from ethically and sustainably sourced iboga under Nagoya Protocol-compliant agreements.
Botanical Coca Extract
Our whole-leaf coca extract drug candidate, developed by Magdalena Biosciences (the joint venture between our subsidiary Filament Health and Jaguar Health) for neuropsychiatric indications including executive dysfunction in ADHD and cognitive deficit in schizophrenia, with a parallel program in post-GLP-1 weight management. Advanced under the FDA's Botanical Guidance from coca leaf ethically sourced in Peru through ENACO.
Manufacturing & Quality
Our drug candidates are produced by our wholly-owned subsidiary, Filament Health, at its in-house, GMP-compliant facility operating under a Health Canada Controlled Substances Dealer's Licence (Level 8), giving Rhelion end-to-end control over the development and supply of standardized, pharmaceutical-grade natural medicines.
Global Reach
Through Filament Health, PEX010 is supplied to research institutions around the world under active supply and licensing agreements, including partners such as Johns Hopkins University, Imperial College London, University of California, San Francisco, University of Oxford, and many more.
Currently supplying to
Beyond clinical trials, PEX010 is supplied to patients through legally authorized compassionate use and named patient access programs in several jurisdictions.
Our People
Co-Founder & CEO, Rhelion
CEO, Filament Health
President, Rhelion
Co-Founder, Filament Health
Chief Financial Officer, Rhelion
Chief Operating Officer, Rhelion
Co-Founder, Filament Health
Special Strategic Advisor, Rhelion
President, Filament Health
Chairman of the Board
Rhelion
Director
Rhelion
Director
Rhelion
Director
Rhelion & Filament Health
Director
Rhelion
Director
Filament Health
Newsroom
Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based organiza…
Read releaseRhelion Life Sciences reflects the Company's evolution into a sharpened focused, science-driven life sciences platform dedicated to psychedelic drug discovery, development, and inn…
Read releaseToronto, Ontario--(Newsfile Corp. - July 16, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontari…
Read releaseStay Connected
Get Rhelion's latest research news and press releases delivered to your inbox. No spam, just meaningful progress in psychiatric and neurological health.
